Latest Stock Buy or Sell? Make More Informed Decisions!

123

Test5555

We would be comfortable buying today, being more aggressive below $230.
Unlock Premium - Try 5i Free  

EPS of $2.04 beat estimates of $1.95; revenue of $811M beat estimates of $792M. EBITDA of $374.6M beat estimates by 5%. Veeva topped consensus, with 3Q revenue rising 16% year over year to $811 million. Subscription services gained 17% on strong R&D Solutions and Crossix demand. Still, management expects about 14 of the top-20 biopharmas to adopt Vault CRM, slightly below its expectations. R&D Solutions sales, up 19%, remain the key growth driver, with momentum in eCOA and RTSM. Commercial subscriptions (39% of revenue) climbed 13% as Vault CRM added 23 new customers, bringing the total to over 115, including eight of the top-20 biopharmas. Management raised fiscal 2026 sales guidance to a midpoint of $3.168 billion from $3.137 billion, supported by expanded cloud adoption. Veeva AI’s agents will launch in December for CRM and commercial content, with broader R&D and Quality rollouts expected in 2026. We would consider the results good. Sellers of the stock seem to be concerned about customer retention, but 14/20 is still pretty solid. But it is that type of a market this month, where only perfection seems to be rewarded.VEEV has more than $6B in cash and we would consider it still quite solid overall at a low (for it) 30X earnings valuation. 
Unlock Premium - Try 5i Free